Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational  Study.

CONCLUSION: In real life, ponatinib is a "niche-drug" reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates.
PMID: 29773429 [PubMed - as supplied by publisher]

Source: Clinical Lymphoma and Myeloma - May 7, 2018 Category: Cancer & Oncology Authors: Shacham-Abulafia A, Raanani P, Lavie D, Volchek Y, Ram R, Helman I, Shargian L, Gourevitch A, Chubar E, Ratzon R, Rozovski U Tags: Clin Lymphoma Myeloma Leuk Source Type: research